Chagas disease - Pipeline Insight, 2022

DelveInsight’s, “Chagas disease – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Chagas disease Understanding
Chagas disease: Overview
Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. About 6 million to 7 million people worldwide are estimated to be infected with T. cruzi, the parasite that causes Chagas Disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as 'kissing bugs', among many other popular names, depending on the geographical area. Chagas Disease presents itself in two phases. The initial acute phase lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood but in most cases, symptoms are absent or mild and unspecific. During the chronic phase, the parasites are hidden mainly in the heart and digestive muscle. Up to 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. Chagas Disease can be treated with benznidazole and also nifurtimox.

""Chagas disease - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas disease pipeline landscape is provided which includes the disease overview and Chagas disease treatment guidelines. The assessment part of the report embraces, in depth Chagas disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Chagas disease R&D. The therapies under development are focused on novel approaches to treat/improve Chagas disease.

Chagas disease Emerging Drugs Chapters
This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chagas disease Emerging Drugs
• Fosravuconazole: Seren Pharmaceuticals
Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma, granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells. The drug is in Phase II stage of development for the treatmen of patients with Chagas Disease.
Further product details are provided in the report……..

Chagas disease: Therapeutic Assessment
This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chagas disease
There are approx. 5+ key companies which are developing the therapies for Chagas disease. The companies which have their Chagas disease drug candidates in the most advanced stage, i.e. Phase II include, Seren Pharmaceuticals.
• Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Chagas disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chagas disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.

Chagas disease Report Insights
• Chagas disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chagas disease Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chagas disease drugs?
• How many Chagas disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chagas disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chagas disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies

• Mitsubishi Tanabe Pharma Corporation
• Eisai Co Ltd
• Selva Therapeutics
• ConserV Bioscience
• Seren Pharmaceuticals
• 7 Hills Pharma